Quest Extends HPV Marketing Deal With Digene for Four More Years | GenomeWeb
NEW YORK (GenomeWeb News) — Digene this week said it has extended by four years a three-year agreement with Quest Diagnostics under which Quest will market Digene’s test for human papillomavirus.
Digene will continue to supply Quest’s labs with the instrumentation and reagents for HPV testing, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.